Results from a new analysis have revealed an improvement in mental health and cognition for Special Operations Forces veterans following a combination of psychedelic treatments.
Results from a major clinical trial have shown that esketamine outperforms one of the standard treatments for treatment-resistant major depression disorder (MDD).
Researchers from the University of Southern Denmark have established a psilocybin microdosing regimen in rats to help advance microdosing research.
Small Pharma has reported positive results from its study investigating the interaction of SSRIs and SPL026 – the company’s native DMT – in patients with Major...
Cybin Inc.
Results from the world’s largest study investigating the ‘naturalistic’ use of psilocybin outside of research settings have shown lasting therapeutic benefits.
The European Medicines Agency (EMA) has updated its general guidelines on the development of medicinal products for Major Depressive Disorder (MDD) to include a section on...
MAPS PBC has published anticipated results from its Phase 3b study that could bring MDMA-assisted therapy closer to Food and Drug Administration (FDA) approval by 2024...
A new research review has explored the use of psilocybin for the treatment of resistant depression.
Findings from a landmark survey have revealed that people with experience using psychedelics exhibited elevated psychological well-being during the COVID-19 pandemic.
